What infections are associated with Tremfya (guselkumab) and what screening, vaccination, and management steps should be taken?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tremfya-Associated Infections

Tremfya (guselkumab) increases the risk of infections, most commonly upper respiratory tract infections, nasopharyngitis, and bronchitis, with serious infections occurring at low rates (approximately 1.0 per 100 patient-years). 1

Infection Risk Profile

The infection spectrum with Tremfya is relatively favorable compared to other immunosuppressants:

Common infections (occurring in ≥1% of patients):

  • Upper respiratory tract infections
  • Nasopharyngitis
  • Bronchitis
  • Gastroenteritis
  • Tinea infections
  • Herpes simplex infections 1

Serious infections: Occur at a rate of approximately 1.0 per 100 patient-years across long-term studies, which is comparable to placebo rates (1.0-2.3 per 100 patient-years) 2, 3. Importantly, no cases of active tuberculosis, Crohn's disease, ulcerative colitis, or opportunistic infections have been reported in psoriasis studies 2, 3. In psoriatic arthritis studies, only 3 opportunistic infections occurred (0.14 per 100 patient-years, all after week 52) 2.

Pre-Treatment Screening Requirements

Before initiating Tremfya, perform the following mandatory screening 4, 1:

Tuberculosis screening:

  • PPD or QuantiFERON-Gold test
  • Chest radiograph if TB test is positive
  • Treat latent TB before starting Tremfya 4, 1

Hepatitis screening:

  • Hepatitis B surface antigen
  • Anti-hepatitis B surface antibody
  • Anti-hepatitis B core antibody
  • Hepatitis C antibody 4

Additional baseline tests:

  • Complete blood count
  • Complete metabolic profile 4

HIV testing: At clinician's discretion based on patient-specific risk factors 4

Vaccination Strategy

Complete all age-appropriate vaccinations before starting Tremfya 1. This is critical because:

  • Avoid all live vaccines during treatment 1
  • Inactivated vaccines can be administered but may have reduced efficacy
  • Plan vaccinations at least 2-4 weeks before initiating therapy when possible

Management of Active Infections

Do not initiate Tremfya in patients with clinically important active infections until the infection resolves or is adequately treated 1. This is an absolute contraindication during active infection.

If infection develops during treatment:

  1. Discontinue Tremfya immediately for febrile illness or any infection requiring antibiotics 4
  2. Complete full antibiotic course if indicated
  3. Wait for complete resolution of all symptoms and signs of infection
  4. Only restart after infection has fully cleared 4

Upon restarting after infection:

  • Loading doses may need to be repeated depending on disease severity and number of missed doses
  • Consider repeating loading doses if the patient is flaring and/or if more than 3-4 half-lives have passed since the previous dose 4

Ongoing Monitoring

During treatment, monitor for:

  • Signs and symptoms of infection at each visit (fever, sweats, chills, cough, shortness of breath, blood in phlegm, warm/red/painful skin lesions, weight loss, diarrhea, abdominal pain, urinary symptoms) 1
  • Periodic history and physical examination, including skin cancer screening 4

Annual TB screening is recommended for high-risk patients (those in contact with active TB cases due to travel, work, or family relationships, or with underlying medical conditions predisposing to TB). For patients not at high risk, screening frequency is at the dermatologist's discretion 4.

Special Considerations

Combination therapy: When combining IL-23 inhibitors like guselkumab with methotrexate, there is an increased risk of infection 4. Weigh this risk carefully and monitor more closely.

Hepatitis B: Limited data suggest guselkumab may be used safely in patients with hepatitis B core antibody positivity without evidence of reactivation 5, though close monitoring is warranted.

The overall safety profile through up to 5 years of treatment (8,662 patient-years of exposure) demonstrates that infection rates remain stable and do not increase with longer duration of therapy 3. This contrasts favorably with TNF inhibitors, which carry higher risks of tuberculosis reactivation and opportunistic infections.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.